Kristin Wynholds is Chief Product Officer of Better Therapeutics, Inc.. Currently has a direct ownership of 225,631 shares of BTTX, which is worth approximately $0. The most recent transaction as insider was on Dec 18, 2023, when has been sold 25,362 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 226K
0% 3M change
12.66% 12M change
Total Value Held $0

Kristin Wynholds Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 18 2023
BUY
Grant, award, or other acquisition
-
25,362 Added 10.1%
225,631 Common Stock
Apr 05 2023
BUY
Grant, award, or other acquisition
-
101,450 Added 33.62%
200,269 Common Stock
Nov 30 2022
BUY
Grant, award, or other acquisition
$4,688 $1.24 p/Share
3,781 Added 3.69%
98,819 Common Stock
May 31 2022
BUY
Grant, award, or other acquisition
$7,735 $1.54 p/Share
5,023 Added 5.02%
95,038 Common Stock
KW

Kristin Wynholds

Chief Product Officer
San Francisco, CA

Track Institutional and Insider Activities on BTTX

Follow Better Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BTTX shares.

Notify only if

Insider Trading

Get notified when an Better Therapeutics, Inc. insider buys or sells BTTX shares.

Notify only if

News

Receive news related to Better Therapeutics, Inc.

Track Activities on BTTX